menu
    • menu

    Company profile for G2GBIO

    NEW Drugs in Dev: 3
    Minakem delivers API, HPAPI, steroids & CDMO services for generics with FDA/GMP certification, regulatory know-how & proven success.

    Virtual Booth

    Contact Supplier

    Boai NKY Pharmaceuticals Ltd. is one of the largest global PVP suppliers.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    Contact Supplier

    Nanjing Well is focused on R&D, production & sales of Pharmaceutical Excipients & Synthetic Lubricating base oils.

    Virtual Booth

    Contact Supplier

    Ever Pharma, highly specialized CDMO in producing complex injectables including high potency & controlled substances, suspensions, etc.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    Contact Supplier

    EVENTS

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    G2G Bio Co., Ltd., founded in 2017 in South Korea and based in Cheongju (Heungdeok-gu), develops innovative sustained-release injectable therapies for conditions including Alzheimer's disease, schizophrenia, diabetes, and obesity.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    G2GBIOkorearepublicofnew Flag
    Country
    Country
    South Korea
    Address
    Address
    21, Uiryodanji-gil, Osong-eup, Heungdeok-gu, Cheongju-si, Chungcheongbuk-do
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://g2gbio.com/en/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    PEGS Boston Summit

    PEGS Boston Summit

    Not Confirmed

    envelop Contact Supplier

    PEGS Boston Summit

    Post an Enquiry

    Meeting

    Drugs in Development

    read-more
    read-more
    • Deals
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Samsung Bioepis, Epis NexLab, and G2GBIO collaborate on long-acting Semaglutide.

    Details:

    The collaboration aims to advance diabetes treatment through the development of Semaglutide, a peptide targeting the GLP-1 receptor.


    Lead Product(s): Semaglutide

    Therapeutic Area: Endocrinology Brand Name: Undisclosed

    Study Phase: PreclinicalProduct Type: Peptide, Unconjugated

    Sponsor: Samsung Bioepis

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Collaboration March 15, 2026

    blank

    01

    G2GBIO

    South Korea
    arrow
    PEGS Boston Summit
    Not Confirmed

    G2GBIO

    South Korea
    arrow
    PEGS Boston Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Semaglutide

    Therapeutic Area : Endocrinology

    Highest Development Status : Preclinical

    Partner/Sponsor/Collaborator : Samsung Bioepis

    Deal Size : Undisclosed

    Deal Type : Collaboration

    DEALS_DEV arrow-down

    Samsung Bioepis, Epis NexLab, and G2GBIO collaborate on long-acting Semaglutide.

    Details : The collaboration aims to advance diabetes treatment through the development of Semaglutide, a peptide targeting the GLP-1 receptor.

    Product Name : Undisclosed

    Product Type : Peptide, Unconjugated

    Upfront Cash : Undisclosed

    March 15, 2026

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Dose-Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics From Single Dose of Intramuscular (IM) and Subcutaneous (SC) Donepezil (G...

    Details:

    GB-5001 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Alzheimer Disease.


    Lead Product(s): GB-5001

    Therapeutic Area: Neurology Brand Name: Undisclosed

    Study Phase: Phase IProduct Type: Undisclosed

    Sponsor: Undisclosed

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable November 13, 2023

    blank

    02

    G2GBIO

    South Korea
    arrow
    PEGS Boston Summit
    Not Confirmed

    G2GBIO

    South Korea
    arrow
    PEGS Boston Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : GB-5001

    Therapeutic Area : Neurology

    Highest Development Status : Phase I

    Partner/Sponsor/Collaborator : Undisclosed

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Dose-Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics From Single Dose of...

    Details : GB-5001 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Alzheimer Disease.

    Product Name : Undisclosed

    Product Type : Undisclosed

    Upfront Cash : Inapplicable

    November 13, 2023

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Dose-Escalation, Single Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GB-6002 Local Infiltration in Healthy ...

    Details:

    GB-6002 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Pain, Postoperative.


    Lead Product(s): GB-6002,Ropivacaine Hydrochloride

    Therapeutic Area: Neurology Brand Name: Undisclosed

    Study Phase: Phase IProduct Type: Undisclosed

    Sponsor: Undisclosed

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable October 23, 2023

    blank

    03

    G2GBIO

    South Korea
    arrow
    PEGS Boston Summit
    Not Confirmed

    G2GBIO

    South Korea
    arrow
    PEGS Boston Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : GB-6002,Ropivacaine Hydrochloride

    Therapeutic Area : Neurology

    Highest Development Status : Phase I

    Partner/Sponsor/Collaborator : Undisclosed

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Dose-Escalation, Single Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Phar...

    Details : GB-6002 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Pain, Postoperative.

    Product Name : Undisclosed

    Product Type : Undisclosed

    Upfront Cash : Inapplicable

    October 23, 2023

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Dose-Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of Donepezil From Single Dose of GB-5001 IM Depot and Aricept® Oral Ta...

    Details:

    GB-5001 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Alzheimer Disease.


    Lead Product(s): GB-5001

    Therapeutic Area: Neurology Brand Name: Undisclosed

    Study Phase: Phase IProduct Type: Undisclosed

    Sponsor: Undisclosed

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable September 02, 2022

    blank

    04

    G2GBIO

    South Korea
    arrow
    PEGS Boston Summit
    Not Confirmed

    G2GBIO

    South Korea
    arrow
    PEGS Boston Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : GB-5001

    Therapeutic Area : Neurology

    Highest Development Status : Phase I

    Partner/Sponsor/Collaborator : Undisclosed

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Dose-Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of Donepezil From S...

    Details : GB-5001 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Alzheimer Disease.

    Product Name : Undisclosed

    Product Type : Undisclosed

    Upfront Cash : Inapplicable

    September 02, 2022

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search